These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 380732)

  • 1. Subcutaneous Corynebacterium parvum in bladder cancer: a controlled study of its immunological effects.
    Purves EC; Snell M; Cope WA; Addison IE; Copland RF; Berenbaum MC
    Br J Urol; 1979 Aug; 51(4):278-82. PubMed ID: 380732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoattractant properties of Corynebacterium parvum and pyran copolymer for human monocytes and neutrophils.
    Majeski JA; Stinnett JD
    J Natl Cancer Inst; 1977 Mar; 58(3):781-3. PubMed ID: 839571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous corynebacterium parvum on peripheral-blood effector cells of cancer patients.
    Gill PG; Waller CA; MacClennan IC; Morris PJ
    Br J Cancer; 1980 May; 41(5):782-9. PubMed ID: 7426303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravesical Corynebacterium parvum on recurrences of superficial tumors of the urinary bladder.
    Raica M
    Anticancer Drugs; 1992 Feb; 3(1):39-42. PubMed ID: 1623214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocyte function in patients with solid neoplasms during immunotherapy with Corynebacterium parvum.
    Scheinberg MA; Masuda A; Maluf JA; Mendes NF
    Cancer; 1978 May; 41(5):1761-4. PubMed ID: 647625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of human monocytes by mediators from lymphocytes stimulated with Corynebacterium parvum.
    Hammerström J; Unsgaard G; Lamvik J
    Acta Pathol Microbiol Scand C; 1979 Jun; 87C(3):167-75. PubMed ID: 484237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary report of the use of levamisole in the treatment of bladder cancer.
    Smith RB; deKernion J; Lincoln B; Skinner DG; Kaufman JJ
    Cancer Treat Rep; 1978 Nov; 62(11):1709-14. PubMed ID: 365325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bladder tumor model response to immunotherapy.
    deKernion JB; Ramming KP; Fraser K
    Natl Cancer Inst Monogr; 1978 Dec; (49):333. PubMed ID: 748789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antigenic relationship between the chemically-induced mouse bladder tumor and Corynebacterium parvum].
    Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1983 Apr; 74(4):560-5. PubMed ID: 6620769
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune function determination in patients with bladder cancer.
    Brosman SA; Fahey JL
    Natl Cancer Inst Monogr; 1978 Dec; (49):321-3. PubMed ID: 311893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro response to Corynebacterium parvum of human effusion lymphocytes isolated from patients with malignant and benign disease.
    Hammerstrøm J
    Acta Pathol Microbiol Scand C; 1980 Aug; 88(4):211-8. PubMed ID: 7446130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microscopic changes of the urinary bladder in patients with primary tumors locally treated with Corynebacterium parvum.
    Raica M; Ioart I; Gurtavenco A
    Morphol Embryol (Bucur); 1989; 35(4):275-7. PubMed ID: 2533966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of immunotherapy with Corynebacterium parvum and methanol extraction residue of BCG administered intravenously on host defense function in cancer patients.
    Hersh EM; Murphy SG; Quesada JR; Gutterman JU; Gschwind CR; Morgan J
    J Natl Cancer Inst; 1981 Jun; 66(6):993-1002. PubMed ID: 6941048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corynebacterium parvum as a therapeutic antitumor agent in mice. II. Local injection.
    Scott MT
    J Natl Cancer Inst; 1974 Sep; 53(3):861-5. PubMed ID: 4213016
    [No Abstract]   [Full Text] [Related]  

  • 15. Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in control of murine transitional cell carcinoma.
    Lau BH; Woolley JL; Marsh CL; Barker GR; Koobs DH; Torrey RR
    J Urol; 1986 Sep; 136(3):701-5. PubMed ID: 3735559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of intramural injection of immunotherapeutic agents on bladder histology and systemic humoral response.
    Albert NE; Sparks FC; Lytton B
    Invest Urol; 1978 Sep; 16(2):134-9. PubMed ID: 361626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The accumulated effects of repeated systemic or local injections of low doses of Corynebacterium parvum in mice.
    Scott MT; Warner SL
    Cancer Res; 1976 Apr; 36(4):1335-8. PubMed ID: 1083289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levamisole in the treatment of non-invasive and invasive bladder cancer: a preliminary report.
    Smith RB; Dekernion J; Baron B; Skinner DG; Kaufman JJ
    J Urol; 1978 Mar; 119(3):347-9. PubMed ID: 347106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate alone or with regional subcutaneous Corynebacterium parvum in the treatment of recurrent and metastatic squamous cancer of the head and neck.
    Vogl SE; Schoenfeld DA; Kaplan BH; Lerner HJ; Horton J; Creech RH; Barnes LE
    Cancer; 1982 Dec; 50(11):2295-300. PubMed ID: 6754063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
    Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
    Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.